Literature DB >> 21220596

Colorectal cancer epigenetics: complex simplicity.

Manon van Engeland1, Sarah Derks, Kim M Smits, Gerrit A Meijer, James G Herman.   

Abstract

Colorectal cancer (CRC) has predominantly been considered a genetic disease, characterized by sequential accumulation of genetic alterations. Growing evidence indicates that epigenetic alterations add an additional layer of complexity to the pathogenesis of CRC, and characterize a subgroup of colorectal cancers with a distinct etiology and prognosis. Epigenetic dysregulation in colorectal cancer is organized at multiple levels, involving DNA methylation, histone modifications, nucleosomal occupancy and remodeling, chromatin looping, and noncoding RNAs. Interactions between these processes and complex associations with genetic alterations have recently been unraveled. It appears that CRC epigenetics will be the paradigm for multistep carcinogenesis, as CRC genetics has been for the past three decades. This review integrates recent data on epigenetic regulation of gene expression in CRC and describes how the understanding of these processes will alter the management of CRC.

Entities:  

Mesh:

Year:  2011        PMID: 21220596     DOI: 10.1200/JCO.2010.28.2319

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  75 in total

Review 1.  Using Epigenetic Therapy to Overcome Chemotherapy Resistance.

Authors:  Julius Strauss; William D Figg
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

2.  CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Authors:  Xiaofei Zhang; Hideki Shimodaira; Hiroshi Soeda; Keigo Komine; Hidekazu Takahashi; Kota Ouchi; Masahiro Inoue; Masanobu Takahashi; Shin Takahashi; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2016-07-19       Impact factor: 3.402

Review 3.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

4.  Aberrant methylated EDNRB can act as a potential diagnostic biomarker in sporadic colorectal cancer while KISS1 is controversial.

Authors:  Reza Mousavi Ardehaie; Shahriar Hashemzadeh; Shahin Behrouz Sharif; Morteza Ghojazadeh; Ladan Teimoori-Toolabi; Ebrahim Sakhinia
Journal:  Bioengineered       Date:  2017-01-31       Impact factor: 3.269

5.  Significant association of EED promoter hypomethylation with colorectal cancer.

Authors:  Xiuru Ying; Ranran Pan; Jie Zhong; Boyi Wu; Yuting Jiang; Jieer Ying; Cong Zhou; Jie Dai; Shuangying Zhao; Yinan Shen; Wei Zhang; Shiwei Duan
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

6.  CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression.

Authors:  Hung-Chih Hsu; Yi-Shiuan Liu; Kai-Chi Tseng; Tsai-Sheng Yang; Chien-Yuh Yeh; Jeng-Fu You; Hsin-Yuan Hung; Shu-Jen Chen; Hua-Chien Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-25       Impact factor: 4.553

Review 7.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

Review 8.  Molecular markers for colorectal cancer screening.

Authors:  Brandon T Dickinson; John Kisiel; David A Ahlquist; William M Grady
Journal:  Gut       Date:  2015-05-20       Impact factor: 23.059

Review 9.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

10.  Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.

Authors:  Yue Guo; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2015-01-29       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.